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Vindication and Isis were two words 
that were coinciding in sentences on 
August 24,1998. On that day the US 
Food and Drug Administration gave 
the go-ahead to fomivirsen, making it 
the first drug belonging to Isis, and 
the first antisense drug ever, to be 
approved. 
Isis Pharmaceuticals, Inc. 
(Carlsbad, California) held up the 
approval as the end of almost ten 
years of doubts and criticism. But not 
everyone was cheering. Antisense 
skeptics are still vocal, and the 
debate over the specificity of 
antisense drugs continues. 
There is one thing that everyone 
involved in antisense research agrees 
upon. “Everyone got into this 
thinking it was an easy thing,” says 
Mark Matteucci, director of 
bioorganic chemistry at Gilead in 
Foster City, California. Gilead 
hammered away at antisense for eight 
years before Glaxo Wellcome pulled 
the funding plug in June 1998. ‘We 
got beat up,” says Matteucci. 
The initial allure of antisense was 
the simplicity of the concept: an 
oligonucleotide complementary to an 
RNA strand should stick to that 
strand and prevent translation of the 
mRNA into protein. Reality has 
involved messier concepts such as 
stability, pharmacokinetics and 
binding to irrelevant proteins. “The 
field was founded on the idea of 
‘give us a sequence and we’ll give 
you a drug,’ but that doesn’t work,” 
says Cy Stein of Columbia 
Liniversity, New York. “It’s much 
more complicated.” 
First the phosphorothioates 
Antisense therapeutics began with a 
cell-culture experiment conducted by 
Paul Zamecnik of Harvard University 
(Cambridge, Massachusetts) in 1978. 
(Zamecnik went on to found 
Hybridon, Inc. (Milford, 
Massachusetts), which is still working 
on antisense therapy.) What made 
antisense a reasonable proposition 
were two innovations of the 1980s: 
automated solid-phase oligonucleotide 
synthesis and phosphorothioates. The 
substitution of a sulfur for one of the 
phosphate oxygens makes the 
phosphorothioate nucleotide chain 
largely resistant to the nucleases that 
would otherwise degrade it. 
Stanley Crooke, the CEO of Isis, 
left Smith Kline and French to found 
Isis in 1989. The phosphorothioate 
technology has taken Isis all the way to 
the cytomegalovirus (CMV) inhibitor 
fomivirsen, a phosphorothioate 
antiviral for the AIDS-related 
condition CMV retinicis. Although this 
condition is not as common as it once 
was, Isis expects that the number of 
potential patients may rise if HIV 
protease drugs begin to fail. 
Next in line is an inhibitor of 
intercellular cell adhesion molecule 1 
(ICAMl); this drug is in both a phase 
III trial for Crohn’s disease (an 
autoimmune condition) and phase II 
trials for several other indications. 
For its anticancer trials, Isis is aiming 
to turn off only the isozyme that is 
defective in the diseased tissue, 
leaving the other isozymes to 
substitute in normal tissues. These 
trials involve inhibitors of protein 
kinase C a and the c-raf kinase 
(phase II), and of Ha-ras (phase I). 
Specific or nonspecific 
This sounds like a perfectly healthy 
drug pipeline for a young company. 
So what is all the grumbling about? 
The main point of contention is 
mechanism of action. “There are 
people who insist vociferously that it 
is all specific effects - they usually 
work for a company - then there are 
people, mostly from academia, who 
insist that it is all nonspecific,” says 
Stein. “I think it is a mixture: there is 
an element of sequence specificity, 
but there have to be large elements 
of nonsequence specificity because 
these phosphorothioates are so 
biologically active.” 
Phosphorothioates, as highly 
charged molecules, are sticky, “Zn 
vitro these molecules have exquisite 
tenacity [for RKA], but in the 
cellular juice there are all these sinks 
and nobody understands that,” says 
Matteucci. 
For Isis that may or may not 
matter. “Not to be Clintonian about 
it, but the words you use are very 
important,” says Stein. “For those 
interested in evaluating gene 
function, nonspecificity is very 
important. For therapeutics, 
nonspecificity may not mean 
anything.” I f  a drug cures a disease 
with minimal side effects, knowing 
the mechanism is an optional extra. 
“For the vast majority of drugs,” 
says Crooke. “the mechanism of 
action remains unproven.” Crooke 
does, however, have a point to prove 
to the scientific community. Although 
Isis cannot take human eye biopsies to 
check if fomivirsen causes degradation 
of virus RNA, Crooke says, “we can 
exclude mechanisms other than 
antisense that we know about.” 
One of those mechanisms is 
prevention of virus binding to the 
outside of the cell. Isis identified this 
mechanism themselves (prompting 
Matteucci to describe the drug as “a 
therapeutic oligonucleotide not a 
therapeutic antisense” and “an 
expensive form of dextran sulfate”), 
but Crooke says the effect is only 
seen at high concentrations of drug 
and virus - conditions that occur 
only in c&o. Furthermore, he says, 
virus transmission in the eye is cell- 
to-cell, so there is no free virus 
available for interaction with the 
drug outside the cell. 
It works, damn it! 
Crooke points to the wealth of human 
studies (with ICAMl and C-rdf 
antisense) and animal studies (for all 
drugs now in clinical trials) that 
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support an antisense mechanism of 
action. “Any reasonable observer that 
looks at all the data has to conclude 
that antisense works. For a set of 
drugs in use now, I don’t think anyone 
has done more to prove mechanism in 
man, ” he says. “We have to overcome 
bias, which always takes a lot more 
data than an initial proof.” 
The results thus far have not, 
however, brought the large 
pharmaceutical companies running. 
“It’s not going to be the vast new 
paradigm for drug discovery,” says 
Matteucci, who is more interested in 
its possible use in defining gene 
function. Novartis is collaborating 
with Isis but, with the cancellation of 
programs at Roche and Gilead/Glaxo, 
no other large company has a public 
commitment to antisense. 
Crooke is philosophical about this 
isolation. “Biotech exists because the 
pharmaceutical industry is very 
reluctant to invest in new 
Fraud at Novartis 
Sometimes data can be too positive. 
As part of their collaboration with 
Isis, Nova& conducted many of the 
xenograft assays with the Isis anti-cancer 
drugs. When the results filtered back to 
Isis, the Isis scientists were puzzled. “We 
were struck by the extraordinary potency 
in the Nova& xenografts; we hadn’t 
seen the same activity: says Choke. 
“We spent almost a year trying to 
understand the difference between our 
results and their results!’ 
The solution was fraud, involving 
many Novattis drugs as well as two Isis 
drugs. “We never dreamt that there 
would be data manipulation - it came as 
a total shock: says Crooke. ‘It was one 
of the darkest days of my life.” 
At the time, the drugs were moving 
from phase I to phase II trials. W&h the 
repetition of assays and refiling of 
regulatory papers, Crooke estimates that 
Isis “probably lost six months.” 
Although Stein claims that “whatever 
real xenograft data there is is only in part 
due to antisense effects: Crooke says 
that Isis published corrections but no 
retractions. “Both drugs were in the 
clinic, and the mechanisms of action 
were still valid. We had other xenograft 
data. We didn’t need to withdraw the 
drugs from the clinic.” 
technologies,” he says. “It made sense 
[for them] to wait.” Plus, he suggests 
that antisense “sounds simple, so it 
can lead to companies setting up what 
they think are meaningful 
investments with four or five people 
who then make no progress.” 
“Antisense never got the 
suspension of disbelief that is needed 
for a new technology to succeed,” 
says Crooke. “As a scientist, that has 
been very hurtful, but as a CEO it’s 
given us about ten years of lead time. 
Now our patent position is so 
dominant it would make more sense 
[for other companies] to collaborate 
with us than compete.” 
Improving the technology 
The promiscuous stickiness of 
phosphorothioates clouds mechanism 
of action, causes side effects, and 
reduces potency. Finding a solution 
is not easy, however, as any new 
compound must satisfy four 
parameters simultaneously: 
decreased protein binding, 
exonuclease resistance, avid RNA 
binding and the ability to be cleaved 
by RNAse H. (Although some 
oligonucleotides work by physically 
blocking translation events. the 
primary mode of a&on is cleavage of 
the RKA by RNAse H, which 
recognizes the DNA-RNA hybrid.) 
Perhaps for this reason, Matteucci 
says that “people have gotten very 
conservative and only tweaked the 
structure. Nobody has come up with 
a quantitative jump over these first 
generation phosphorothioates.” 
Crooke says that Isis has screened 
approximately 4000 analogs to 
improve on phosphorothioates, and 
the winner thus far is a variant with a 
methoxy-ethyl group at the 2’ 
position of the sugar (the position that 
has a hydroxyl group in RNA but not 
DNA). The analog is incorporated as 
a cap at either end of the 
oligonucleotide, with 
phosphorothioate bases in the middle. 
A second-generation CM\’ 
inhibitor of this type is in phase I 
trials for CMV retinitis. Crooke says 
the modification increases both 
potency and half-life fivefold, so 
smaller doses can be given perhaps 
every two weeks rather than every 
two days. In combination with a bile- 
salt formulation, Crooke says it 
should be possible to take the new 
drug orally with up to 30% 
bioavailability (fomivirsen is injected 
into the eye; the other drugs are 
given intravenously). Furthermore, 
the second-generation inhibitors 
show fivefold less immune 
stimulation and complement 
activation, two of the most significant 
side effects of phosphorothioates. Isis 
will continue with clinical trials of 
the other phosphorothioate drugs, 
however, given that they have a lead 
time of up to four years. 
The phosphorothioates appear to 
enter the cell following charge- 
dependent interactions with surface 
proteins: this results in a tissue 
distribution that is very uneven. 
Pendant modifications could target the 
drugs to a particular surface protein in 
a particular tissue. Although this could 
add cost to an already large and 
expensive molecule, Crooke says he is 
keeping the modifications simple. 
High-throughput patents 
In selecting the site to attack on any 
mRNA - no simple task given the 
secondary structure in many mRNAs 
- Isis has rejected prediction 
programs and opted for high- 
throughput screening fed by a 
96-well synthesizer. “We can take 
your gene on Monday, screen 50 sites 
with first- and second-generation 
chemistry, confirm actives and file a 
patent by Wednesday,” says Crooke. 
“We’ve automated patenting so the 
data drops into the patent format. 
With a tiny group next year, we will 
identify antisense to approximately 
100 RKL4s and file patents. In one 
year we will do what took the first 
seven.” The approval of fomivirsen, 
he says, marks only “the end of the 
beginning of this technology.” 
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